If you have a certain kind of breathing condition, your doctor might suggest Symbicort as a treatment option. It’s a prescription drug used to treat the following: chronic obstructive pulmonary ...

If you’re looking at treatment options for certain lung conditions, you may want to learn more about Symbicort. Symbicort is a prescription drug that’s used to treat: chronic obstructive ...

London, UK, Thursday 23 March 2023 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing ...

26, 2023, in South San Francisco, Calif. Photo: Aaron M. Sprecher (AP) AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for ...

New data showed that using SYMBICORT® for asthma provides a rapid and clinically significant bronchodilatory response and improvement in lung function. New data showed that using SYMBICORT® for ...

[8] Dr Brian Lipworth, Scottish Centre for Respiratory Research Ninewells Hospital, University of Dundee, said: “The SMC’s decision is based on robust data from four different clinical trials ...

Viatris’ shares today sell at an attractive valuation. This extended the lapse date of a key patent for Symbicort to July 2023. But with just six months until that patent expires, Viatris could ...

Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...

The cap is effective June 1 and will apply to the company’s entire range of inhaler products used to treat asthma and chronic obstructive pulmonary disease, including inhalers Symbicort ...

Trust Specialists Hospital, in partnership with AstraZeneca, has marked World Asthma Day 2025 with a renewed commitment to asthma care. Under the theme ‘Make inhaled treatment accessible to all ...